多西他赛联合FOLFOX方案治疗进展期胃癌临床疗效观察  

Clinical observation of Docetaxel combined with FOLFOX on advanced gastric cancer

作　　者：王思亮[1] 陈晓东[1] 吴荣[1] 钱昊初[1] 

机构地区：[1]中国医科大学附属盛京医院,辽宁沈阳110022

出　　处：《实用临床医药杂志》2011年第9期59-61,共3页Journal of Clinical Medicine in Practice

摘　　要：目的观察多西他赛联合FOLFOX方案治疗进展期胃癌的疗效及不良反应。方法对32例进展期胃癌行多西他赛联合FOLFOX方案化疗,3周为1周期,完成2个周期后评价疗效。结果化疗总有效率37.5%,中位疾病进展时间6.3个月,中位生存期10.4个月。不良反应以骨髓抑制、胃肠道反应和静脉炎为主。结论多西他赛联合FOLFOX方案治疗进展期胃癌有较好的疗效,毒副作用可以耐受,可作为进展期胃癌一线治疗方案。Objective To evaluate the efficacy and toxicity of Docetaxel（DTX） combined with FOLFOX in treating patients with advanced gastric carcinoma.Methods Thirty-two patients were treated with Docetaxel and FOLFOX regimen,（1 cycle=every 3 weeks）.Tumor assessment was done after 2 cycles.Results The overall response rate was 37.5%,and the median TTP was 6.3 months.Median survival time was 10.4 months.The main toxicity was nyelosuppression,gastroin-testinal tract reaction and phlebitis.Conclusion Docetaxel combined with FOLFOX regimen is active and is less toxic and the regimen can be applied to the first line chemotherapy.

关 键 词：多西他赛 FOLFOX 进展期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]